Efficacy
Sub Groups
XELJANZ demonstrates efficacy in patients who have previously failed TNFi agents1
Remission in patients with and without prior TNFi failure during induction1
Regardless of prior TNFi use, XELJANZ was more effective than placebo at 10 mg BID1​​​​​​​
Central reading of endoscopic findings was used for eligibility and primary and key secondary efficacy endpoint analyses.
In OCTAVE Induction 1, patients had a mean Total Mayo score of 9 at baseline (n=598). 51% had previously failed TNFi; 75% corticosteroids; 74% immunosuppressant therapy. Previous treatment failure was determined by the investigator. 
In OCTAVE Induction 2, patients had a mean Total Mayo score of 9 at baseline (n=541). 52% had previously failed TNFi; 71% corticosteroids; 69% immunosuppressant therapy. Previous treatment failure was determined by the investigator.
Remission of patients with and without prior TNFi failure during maintenance1
Regardless of prior TNFi use, XELJANZ was more effective than placebo at both 5 mg and 10 mg BID1​​​​​​​
 
Central reading of endoscopic findings was used for eligibility and primary and key secondary efficacy endpoint analyses.1
Patients had a mean Total Mayo score of 3.3 at the baseline of OCTAVE Sustain (n=593). 45% of patients had failed previously failed TNFi; 75% corticosteroids; 70% immunosuppressant therapy.1
 
Explore more
Dosing in UC
VISIT PAGE
>
BID=twice daily; TNFi=tumour necrosis factor inhibitor.
References
  1.  Dubinsky MC et al. Poster presented at: World Congress of Gastroenterology at the American College of Gastroenterology Annual Scientific Meeting; October 13–18, 2017, Orlando, FL, USA.
PP-XEL-GBR-3121. August 2021
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.